Marksans Pharma Limited (MARKSANS) Stock Statistics & Valuation Metrics

Marksans Pharma Limited has a market cap or net worth of ₹118.39B. The enterprise value is ₹114.61B.

Marksans Pharma Limited has 453,163,760 shares outstanding. The number of shares has decreased by -2.65% in one year.

Marksans Pharma Limited’s return on equity (ROE) is 0.15 and return on invested capital (ROIC) is 30.38%.

The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.

In the last 12 months, Marksans Pharma Limited had revenue of 26.23B and earned 3.81B in profits. Earnings per share was 8.40.

In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.

Marksans Pharma Limited pays an annual dividend of ₹0.6, resulting in a dividend yield of 0.23%

Marksans Pharma Limited upcoming earnings date is Aug 7, 2025, TBA (Confirmed).

Marksans Pharma Limited as a current ratio of 4.62, with Debt / Equity ratio of 13.05%

In the past 12 months, Marksans Pharma Limited has paid 1.21B in taxes.

Marksans Pharma Limited EV to EBITDA ratio is 18.30, with an EV/FCF ratio of 286.69.

Marksans Pharma Limited has ₹7.05B in cash and marketable securities with ₹3.22B in debt, giving a net cash position of -₹3.83B billion.

Gross margin is 52.55%, with operating margin of 43.04%, and net profit margin of 14.51%.

The average price target for Marksans Pharma Limited is ―, which is 11.43% higher than the current price. The consensus rating is ―